Results 1 to 10 of about 2,019 (146)

Computational analysis and validation of UGT1A1/4 missense variants impacting tecovirimat metabolism in monkeypox patients [PDF]

Frontiers in Systems Biology
IntroductionSingle nucleotide polymorphisms (SNPs) in genes encoding drug-metabolizing enzymes can significantly impact a patient’s response to medication.
Amro A. Abdelazim, Sameh E. Hassanein, Sameh E. Hassanein, Mohamad Maged, Nada S. Al-Theyab, Itoh Kimiko, Kotb A. Attia   +6 more
doaj   +2 more sources

Structural and dynamic insights into F13L variations in monkeypox virus and their impact on tecovirimat resistance [PDF]

Virology Journal
The recent global outbreak of Monkeypox virus since 2022, particularly outside Africa, has underscored its significant threat to public health. Genomic surveillance from multiple countries has revealed diverse genetic variations among circulating ...
Yao Wang, Cuiling Wu, Yingzhi Wang, Tao Li   +3 more
doaj   +2 more sources

Mpox in Europe, 2022–2026: A Scoping Review of Viral Clades, Host Determinants of Severity and Antiviral Therapy [PDF]

Viruses
The 2022–2024 mpox outbreak in Europe was dominated by MPXV Clade IIb and generally mild, but recent Clade I/Ib detections and early local transmission have changed preparedness needs.
Filippos Sofos, Zoi D. Pana, Dimitris Drikakis   +2 more
doaj   +2 more sources

Evaluating the advancements and efficacies in pharmacological Mpox treatments: a comprehensive review [PDF]

Frontiers in Pharmacology
Monkeypox, now known as Mpox, has reemerged as a serious public health threat due to an increasing number of outbreaks outside its primary endemic regions. Although virologically similar to smallpox, smallpox therapy is not specifically approved for Mpox.
Shuaibu Abdullahi Hudu, Shuaibu Abdullahi Hudu, Najlaa Saadi, Albashir Tahir, Abdulgafar Olayiwola Jimoh, Aliyu Haruna, Aliyu Haruna   +6 more
doaj   +2 more sources

Assessment of three antiviral compounds against Borealpox virus infection in a mouse model [PDF]

Emerging Microbes and Infections
Borealpox virus (BRPV) is a zoonotic orthopoxvirus which was first documented in Alaska in 2015. Although most human infections are mild, a recent fatal case in an immunocompromised individual highlights the importance of studying this emerging pathogen.
Jérémie Prévost, Nikesh Tailor, Angela Sloan, Kathleen Fulton, Sarah J. Medina, Jonathan Audet, Geoff Soule, David Safronetz   +7 more
doaj   +2 more sources

Ocular mpox presenting as sclerokeratouveitis: A case report [PDF]

IDCases
Purpose: To describe a case of mpox-associated ocular disease in an HIV-infected patient. Case report: A 50-year-old man presented with severe ocular inflammation including corneal ulceration, scleral involvement and anterior uveitis.
N. Domènech-López, P. Marjalizo, I. Bourleau, A. Casablanca-Piñera, L. Moura, J. Rosinés-Fonoll, J. Torras-Sanvicens   +6 more
doaj   +2 more sources

A Glance at the Development and Patent Literature of Tecovirimat: The First-in-Class Therapy for Emerging Monkeypox Outbreak

Viruses, 2022
Monkeypox disease (MPX) is currently considered a global threat after COVID-19. European Medicines Agency (EMA) approved Tecovirimat in capsule dosage form (200 mg) as the first treatment for MPX in January 2022.
Mazen Almehmadi, Mamdouh Allahyani, Ahad Amer Alsaiari, Mohammed Kanan Alshammari, Abrar Saleh Alharbi, Khansa Hamza Hussain, Lojain Ibrahim Alsubaihi, Mehnaz Kamal, Shahad Saleh Alotaibi, Atheer Nasser Alotaibi, Afeefah Awaid Aldhafeeri, Mohd Imran   +11 more
doaj   +1 more source

Tecovirimat Resistance in Mpox Patients, United States, 2022–2023

Emerging Infectious Diseases, 2023
During the 2022 multinational outbreak of monkeypox virus (MPXV) infection, the antiviral drug tecovirimat (TPOXX; SIGA Technologies, Inc., https://www.siga.com) was deployed in the United States on a large scale for the first time.
Todd G. Smith, Crystal M. Gigante, Nhien T. Wynn, Audrey Matheny, Whitni Davidson, Yong Yang, Rene Edgar Condori, Kyle O’Connell, Lynsey Kovar, Tracie L. Williams, Yon C. Yu, Brett W. Petersen, Nicolle Baird, David Lowe, Yu Li, Panayampalli S. Satheshkumar, Christina L. Hutson   +16 more
doaj   +1 more source

Successful Outcome after Treatment with Cidofovir, Vaccinia, and Extended Course of Tecovirimat in a Newly-Diagnosed HIV Patient with Severe Mpox: A Case Report

Vaccines, 2023
Purpose: To report a case of severe mpox in a newly diagnosed HIV patient concerning for Immune Reconstitution Inflammatory Syndrome (IRIS) and/or tecovirimat resistance and to describe the management approach in the setting of refractory disease.
Andres E. Martinez, Paola Frattaroli, Christine A. Vu, Lizy Paniagua, Joel Mintz, Andres Bravo-Gonzalez, Paola Zamudio, Astrid Barco, Aruna Rampersad, Paola Lichtenberger, Jose A. Gonzales-Zamora   +10 more
doaj   +1 more source

The use of antivirals in the treatment of human monkeypox outbreaks: a systematic review

International Journal of Infectious Diseases, 2023
Objectives: Human monkeypox virus (MPXV) infection is a recently declared public health emergency of international concern by the World Health Organization. Besides, there is scant literature available on the use of antivirals in MPXV infection.
Muhammad Aaqib Shamim, Bijaya Kumar Padhi, Prakasini Satapathy, Sai D Veeramachaneni, Chandrima Chatterjee, Snehasish Tripathy, Naushaba Akhtar, Anindita Pradhan, Pradeep Dwivedi, Aroop Mohanty, Alfonso J. Rodriguez-Morales, Ranjit Sah, Ala'a B. Al-Tammemi, Jaffar A. Al-Tawfiq, Behdin Nowrouzi-Kia, Vijay Kumar Chattu   +15 more
doaj   +1 more source